AI Article Synopsis

  • - The COVID-19 pandemic, caused by the SARS-CoV-2 virus, is a significant global health crisis, leading to numerous daily deaths and lacking effective medication to combat it.
  • - Natural products from various medicinal plants, such as Artemisia annua and Astragalus membranaceus, have shown promising effects against coronavirus and could serve as potential treatments.
  • - The text identifies 93 antiviral drug candidates, including various plant-derived compounds, that could be researched further for their effectiveness in treating COVID-19 and other respiratory viruses.

Article Abstract

The whole world is entangled by the coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), people are dying in thousands each day, and without an actual medication, it seems not possible for the bringing this global health crisis to a stop. Natural products have been in constant use since ancient times and are proven by time to be effective. Crude extract or pure compounds isolated from medicinal plants and/or herbs such as Artemisia annua, Agastache rugosa, Astragalus membranaceus, Cassia alata, Ecklonia cava, Gymnema sylvestre, Glycyrrhizae uralensis, Houttuynia cordata, Lindera aggregata, Lycoris radiata, Mollugo cerviana, Polygonum multiflorum, Pyrrosia lingua, Saposhnikoviae divaricate, Tinospora cordifolia etc. have shown promising inhibitory effect against coronavirus. Several molecules, including acacetin, amentoflavone, allicin, blancoxanthone, curcumin, daidzein, diosmin, epigallocatechin-gallate, emodin, hesperidin, herbacetin, hirsutenone, iguesterin, jubanine G, kaempferol, lycorine, pectolinarin, phloroeckol, silvestrol, tanshinone I, taxifolin, rhoifolin, xanthoangelol E, zingerol etc. isolated from plants could also be potential drug candidates against COVID-19. Moreover, these could also show promising inhibitory effects against influenza-parainfluenza viruses, respiratory syncytial virus, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome coronavirus (MERS-CoV). Here, we have reported 93 antiviral drug candidates which could be a potential area of research in drug discovery.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675695PMC
http://dx.doi.org/10.1002/ptr.6893DOI Listing

Publication Analysis

Top Keywords

respiratory syndrome
12
medicinal plants
8
severe acute
8
acute respiratory
8
syndrome coronavirus
8
promising inhibitory
8
drug candidates
8
potential roles
4
roles medicinal
4
plants treatment
4

Similar Publications

The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting.

PLOS Glob Public Health

January 2025

Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, Arizona, United States of America.

Omicron is the comparatively most transmissible and contagious variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). We conducted a seroprevalence study from March 1-3, 2022, to investigate the seroprevalence of SARS-CoV-2 antibodies among individuals aged 18 years and older after the Omicron outbreak. The seroprevalence of anti-receptor binding domain (RBD) antibodies was found to be 96.

View Article and Find Full Text PDF

Background: 22q11 deletion syndrome consists of a variable grouping of phenotypic features and immunological defects secondary to the loss of genetic material located in the 22q11.2 band. The 22q11 deletion spectrum encompasses different syndromes related to the same etiology and with overlapping anomalies, including DiGeorge syndrome, velocardiofacial syndrome, among others.

View Article and Find Full Text PDF

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus are primarily transmitted through droplets or aerosols from patients. The inactivation effects of existing virus control techniques may vary depending on the environmental factors. Therefore, it is important to establish a suitable evaluation system for assessing virus control techniques against airborne viruses for further real-world implementation.

View Article and Find Full Text PDF

Objective: This study aimed to develop and validate the modified irritant gas syndrome agent (IGSA) criteria, utilizing readily available triage information and epidemiologic data to efficiently segregate patients based on the severity of hydrofluoric acid (HFA) exposure.

Methods: A retrospective analysis of 160 patients exposed to HFA was performed to develop the criteria and assess the criteria's efficacy, focusing on age, respiratory rate, and compliance with IGSA standards. The criteria's validity was assessed by comparing clinical outcomes between patients meeting the modified IGSA (mIGSA) criteria and those who did not as external and internal.

View Article and Find Full Text PDF

Only a few studies have examined the effects of coronavirus disease 2019 (COVID-19) and influenza on clinical outcomes in pediatric patients. Furthermore, no meta-analysis has assessed the impact of these diseases on adverse outcomes. This study aims to compare the clinical outcomes of COVID-19 and influenza in pediatric patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!